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Abstract
Background:  Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine
implicated in the pathogenesis of a number of human diseases including inflammatory neurological
diseases. Its role in the pathogenesis of cerebral malaria is unknown. Cerebral malaria is a life-
threatening complication of falciparum malaria with approximately 20%–30% of patients dying
despite appropriate anti-malarial treatment. The reason for this cerebral malaria mortality is still
unknown although host proinflammatory factors have been shown to be evidently important. The
current study investigated the role of circulating MIF in the pathogenesis and outcomes of cerebral
malaria.
Findings: Three categories of subjects contributed to this study: healthy controls subjects, mild
malaria patients, and cerebral malaria patients. The cerebral malaria patients were further grouped
into cerebral malaria survivors and cerebral malaria non-survivors. MIF levels in the peripheral
blood plasma, obtained at the time of enrollment, were measured using standard ELISA methods.
In logistic regression on cerebral malaria patients, log MIF levels were found to be significantly
associated with fatal outcome (odds ratio 4.0; 95%CI 1.6, 9.8; p = 0.003). In multinomial logistic
regression log MIF levels were found to be significantly associated with patient category (p = 0.004).
Conclusion: This study suggests that elevated levels of MIF in the peripheral blood of cerebral
malaria patients may be associated with fatal outcomes.
Background
Macrophage migration inhibitory factor (MIF) is a multi-
functional cytokine whose role as an important regulator
of immune and inflammatory responses in a number of
human diseases, such as sepsis, rheumatoid arthritis, can-
cer and inflammatory neurological diseases, has been
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confirmed (reviewed in [1]). Its role in the pathogenesis
of malaria has only begun to be investigated. The poten-
tial role of MIF in the pathogenesis of malaria anemia was
evident from an experimental study using a mouse model
in which high MIF levels were associated with malaria
anemia [2]. However, most human studies conducted
with African children have reported lower levels of MIF in
malaria infected children compared to healthy asympto-
matic children [3]. In addition, a recent study demon-
strated a decline in MIF levels during an experimental
malaria infection using healthy European volunteers [4].
These studies have suggested a protective role for MIF dur-
ing malaria. However, a few studies have reported an
increase in MIF levels during malaria infections [2,5,6].
Elevated MIF levels were observed in malaria infected
Zambian children compared to uninfected children [2].
Pregnant women with placental malaria infection demon-
strated significantly higher levels of MIF in the placental
intervillous blood compared to uninfected pregnant
women [5,6].
The role of circulating MIF in the pathogenesis of cerebral
malaria (CM) and its outcome has not been investigated.
CM is a life-threatening complication of falciparum
malaria; approximately 20% to 30% of CM patients die
despite anti-malarial treatment and some survivors
develop neurological complications [7]. It is not known
why subsets of CM patients develop fatal complications
and it is hoped that a better understanding of this process
can lead to development of adjunct therapies that can
improve treatment outcomes and aid in the identification
of biomarkers associated with severe outcomes. Recent
studies have implicated several factors involved in the
host inflammatory pathway in the pathogenesis associ-
ated with CM [8-11]. In our own recent study with this
same cohort of subjects, we observed that Interferon
inducible protein 10 (IP-10), soluble tumor necrosis fac-
tor receptor 2 (sTNF-R2) and sFas were independently
associated with increased risk of CM-associated mortality
and that CM non-survivors had significantly lower level of
the neuroprotective factor vascular endothelia growth fac-
tor (VEGF) when compared to other groups [10]. As a fol-
low up to this study and given the role of MIF in sepsis
associated death and other neurological disorders, we
hypothesized that elevated levels of MIF may be involved
in CM-associated death.
Methods
For this investigation, plasma samples obtained from a
well characterized prospective cohort study of malaria
conducted in Jabalpur, India were utilized. This study area
is a low endemic area with seasonal transmission of
malaria. The study details were recently reported else-
where [10]. This cohort had three groups of patients,
namely: healthy controls (HC) who did not have malaria
or other febrile illness, mild malaria (MM) patients who
had fever with P. falciparum parasitemia of <25,000 para-
sites/μl of blood (detected microscopically from blood
smears) and no evidence of impaired consciousness, sei-
zures, and no past history of mental illness, meningitis, or
accidental head injury, and cerebral malaria (CM)
patients who met the World Health Organization's criteria
for CM [12] with a Glasgow coma score of ≤8, positive
blood smear for P. falciparum and no other clinically evi-
dent cause of impaired consciousness. Peripheral blood
samples were collected from the subjects after informed
consent was obtained and plasma samples were stored at
-80°C until used for experiments. A total of 138 samples
were available for this investigation of which 23 were
from HC, 47 were from MM patients, 54 were from CM
survivors (CMS) and 14 were from CM non-survivors
(CMNS). Plasma MIF levels were determined using stand-
ard ELISA methods as described previously [6]. Pairwise
comparisons of MIF levels in the four groups were per-
formed through the Wilcoxon rank sum test. Logistic
regression was used for the CM patients to determine if
there was an association with fatal outcome and log MIF
levels. Multinomial logistic regression was used for all
patients to determine if there was an association with
patient category (HC, MM, CMS, and CMNS) and log MIF
levels, using HC as the reference group. Significance for
the pairwise comparisons was assessed at the Bonferroni
corrected alpha level of 0.008, and significance for the
logistic regressions was assessed at an alpha level of 0.05.
Results
The highest median MIF level was in the CMNS group, fol-
lowed by HC, MM, and CMS, respectively (Figure 1).
None of the pairwise comparisons showed any significant
differences between the groups at the Bonferroni cor-
rected alpha level of 0.008 (data not shown). The logistic
regression on CM patients showed a significant associa-
tion between fatal outcome and log MIF levels, with
increasing log MIF levels increasing the odds of fatal out-
come (odds ratio 4.0; 95%CI 1.6, 9.8; p = 0.003). The
multinomial logistic regression on all patients showed
that log MIF levels were significantly associated with
patient category (p = 0.004). The odds ratios show that the
odds of being a CMS patient compared to HC significantly
decrease as log MIF increases (OR estimate 0.5; 95% CI
(0.2, 0.9)). However, the odds of being a MM patient or
CMNS patient compared to HC does not significantly
change as log MIF increases (MM OR estimate 0.6; 95% CI
(0.3, 1.1); CMNS OR estimate 2.1; 95% CI (0.9, 5.3), Fig-
ure 2).
Figure 2 is a plot of log MIF levels versus odds ratio for
each patient group compared to the reference group (HC).
This plot illustrates that the odds of CM or MM compared
to HC decrease as log MIF increases, while the odds ofBMC Research Notes 2009, 2:36 http://www.biomedcentral.com/1756-0500/2/36
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CMNS compared to HC increase as log MIF increases (this
is supported by the odds ratio point estimates). Further-
more, it is noted that the odds ratios in each of these three
comparisons cross the null value of 1 at a log MIF value of
approximately 10.8 (indicated with an arrow in Figure 2).
This indicates that for log MIF values less than 10.8 a
patient is more likely to belong to the CM or MM group
than the HC group, and for log MIF values greater than
10.8 the patient is less likely to belong to the CM or MM
group than the HC group. Conversely, for log MIF values
less than 10.8 a patient is less likely to belong to the
CMNS group than the HC group, and for log MIF values
greater than 10.8 the patient is more likely to belong to
the CMNS group than the HC group.
Discussion
Several studies have demonstrated that elevated MIF levels
were associated with inflammatory neurological disorders
such as neuron-Behcet's disease and different forms of
multiple sclerosis (reviewed in [1]). In a recent study, high
plasma MIF levels were shown to be associated with early
death in patients with severe sepsis [13]. Collectively,
these findings are consistent with our hypothesis that ele-
vated MIF levels in CM patients may be a risk factor for
mortality. However, high MIF levels alone may not
explain the CM-associated fatality in CMNS. It is plausible
to postulate that the role of MIF in fatal CM outcome is in
concert with other host factors. Indeed, host factors
involved in inflammatory pathway such as TNF-α and IP-
10 have been implicated in the CM associated mortality
[8,10]. Since MIF up regulates the proinflammatory
responses of both T- lymphocytes and macrophages, we
speculate that it may act in concert with these proinflam-
matory factors in inducing fatal complications in CM
patients. It is slightly counterintuitive that both logistic
regression and multinomial logistic regression showed
significant associations with log MIF levels and outcome
or patient category, while the pairwise comparisons did
not show significant differences in median MIF level
between the patient groups. This could be due to the con-
servative nature of the Bonferroni correction which
reduces the power to find significant differences if they do
exist. However, further large scale studies are needed to
confirm our findings and to investigate the potential
mechanisms involved.
The observation from this study that MM and CMS
patients had low MIF levels compared to HC may suggest
a protective role of MIF against malaria and is consistent
with previous studies that demonstrated significantly
reduced circulating MIF levels in children with acute
malaria infection compared to matched healthy controls
[3]. Although the reasons for the down regulation of MIF
Peripheral blood MIF levels in different groups of patients Figure 1
Peripheral blood MIF levels in different groups of 
patients. The log median values of plasma levels of MIF in 
healthy controls (HC, n = 23), mild malaria patients (MM, n = 
47), cerebral malaria survivors (CMS, n = 54) and cerebral 
malaria non-survivors (CMNS, n = 14) are plotted as box 
plot with 25th- and 75th-percentile values represented by 
the bottom and top edges of boxes. Small filled diamonds 
indicate values that fall outside of the error bars. Differences 
were not significant after Bonferroni correction at alpha 
0.008.
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MIF levels are associated with different disease outcomes Figure 2
MIF levels are associated with different disease out-
comes. The results from a multinomial logistic regression 
analysis are reported. The odds ratios of disease outcomes 
were plotted against log MIF levels. The different lines repre-
sent comparisons of the disease category to the reference 
healthy control (HC) group, as indicated in the figure legend. 
A horizontal reference line was drawn at odds ratio of 1 at 
which point there is a difference between a harmful and a 
protective factor. It is noted that the odds ratios in each of 
these three comparisons cross the null value of 1 at a log MIF 
value of approximately 10.8 (arrow).BMC Research Notes 2009, 2:36 http://www.biomedcentral.com/1756-0500/2/36
Page 4 of 4
(page number not for citation purposes)
in malaria patients is not well understood, a recent study
suggest that this may be due to the decrease in the number
of circulating lymphocytes observed during malaria infec-
tion [4]. Unlike in CMNS patients, higher levels of MIF
appear to confer protective advantage to severe malaria
anemia patients [14]. It has been reported that patients
with an inherent ability to produce higher MIF levels are
more likely to be protected from severe malaria anemia
[14].
Results from this study suggest a dual role for MIF during
malaria infection: a protective and pathological role. This
duality in MIF functions has been suggested previously
using in vitro studies (reviewed in [1,15]). However, the
mechanisms involved in MIF-associated diseases are still
incompletely understood and points to the fact that little
is known about the role of this factor in cerebral malaria
patients.
Conclusion
Overall, these studies suggest that MIF may play a role in
the fatal outcomes associated with CM. However, further
studies are needed to better understand the role of MIF in
malaria pathogenesis
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